Sharobel

Norethindrone


Northstar Rx Llc
Human Prescription Drug
NDC 16714-441
Sharobel also known as Norethindrone is a human prescription drug labeled by 'Northstar Rx Llc'. National Drug Code (NDC) number for Sharobel is 16714-441. This drug is available in dosage form of Kit. The names of the active, medicinal ingredients in Sharobel drug includes . The currest status of Sharobel drug is Active.

Drug Information:

Drug NDC: 16714-441
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sharobel
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Norethindrone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Northstar Rx Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Kit
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Sep, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA200961
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Northstar Rx LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:198042
748961
1539955
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
16714-441-011 BLISTER PACK in 1 PACKET (16714-441-01) / 1 KIT in 1 BLISTER PACK13 Sep, 2013N/ANo
16714-441-021 BLISTER PACK in 1 CARTON (16714-441-02) / 1 KIT in 1 BLISTER PACK01 Jan, 2020N/ANo
16714-441-033 BLISTER PACK in 1 CARTON (16714-441-03) / 1 KIT in 1 BLISTER PACK01 Jan, 2020N/ANo
16714-441-046 BLISTER PACK in 1 CARTON (16714-441-04) / 1 KIT in 1 BLISTER PACK13 Sep, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sharobel norethindrone sharobel norethindrone norethindrone norethindrone fd&c blue no. 1 fd&c yellow no. 6 titanium dioxide polyvinyl alcohol talc polyethylene glycol 3350 lecithin, soybean hypromelloses lactose monohydrate magnesium stearate starch, corn v2

Boxed Warning:

Warning cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. this risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. women who use oral contraceptives should be strongly advised not to smoke.

Indications and Usage:

Indications and usage 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. however, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. sharobel ™ tablets have not been studied for and are not indicated for use in emergency contraception.

Warnings:

Warnings cigarette smoking increases the risk of serious cardiovascular disease. women who use oral contraceptives should be strongly advised not to smoke. sharobel ™ does not contain estrogen and, therefore, this insert does not discuss the serious health risks that have been associated with the estrogen component of combined oral contraceptives (cocs). the healthcare professional is referred to the prescribing information of combined oral contraceptives for a discussion of those risks. the relationship between progestin-only oral contraceptives and these risks is not fully defined. the healthcare professional should remain alert to the earliest manifestation of symptoms of any serious disease and discontinue oral contraceptive therapy when appropriate. 1. ectopic pregnancy the incidence of ectopic pregnancies for progestin-only oral contraceptive users is 5 per 1000 woman-years. up to 10% of pregnancies reported in clinical studies of progestin-only oral contraceptive users are
extrauterine. although symptoms of ectopic pregnancy should be watched for, a history of ectopic pregnancy need not be considered a contraindication to use of this contraceptive method. healthcare professionals should be alert to the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain while on progestin-only oral contraceptives. 2. delayed follicular atresia/ovarian cysts if follicular development occurs, atresia of the follicle is sometimes delayed and the follicle may continue to grow beyond the size it would attain in a normal cycle. generally these enlarged follicles disappear spontaneously. often they are asymptomatic; in some cases they are associated with mild abdominal pain. rarely they may twist or rupture, requiring surgical intervention. 3. irregular genital bleeding irregular menstrual patterns are common among women using progestin-only oral contraceptives. if genital bleeding is suggestive of infection, malignancy or other abnormal conditions, such nonpharmacologic causes should be ruled out. if prolonged amenorrhea occurs, the possibility of pregnancy should be evaluated. 4. carcinoma of the breast and reproductive organs some epidemiological studies of oral contraceptive users have reported an increased relative risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. these studies have predominantly involved combined oral contraceptives and there is insufficient data to determine whether the use of pops similarly increases the risk. a meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years. this increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. there was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use. women with breast cancer should not use oral contraceptives because the role of female hormones in breast cancer has not been fully determined. some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. however, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. there is insufficient data to determine whether the use of pops increases the risk of developing cervical intraepithelial neoplasia. 5. hepatic neoplasia benign hepatic adenomas are associated with combined oral contraceptive use, although the incidence of benign tumors is rare in the united states. rupture of benign, hepatic adenomas may cause death through intra-abdominal hemorrhage. studies have shown an increased risk of developing hepatocellular carcinoma in combined oral contraceptive users. however, these cancers are rare in the u.s. there is insufficient data to determine whether pops increase the risk of developing hepatic neoplasia.

Dosage and Administration:

Dosage and administration to achieve maximum contraceptive effectiveness, sharobel™ must be taken exactly as directed. one tablet is taken every day, at the same time. administration is continuous, with no interruption between pill packs. see detailed patient labeling for detailed instruction.

Contraindications:

Contraindications progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: known or suspected pregnancy known or suspected carcinoma of the breast undiagnosed abnormal genital bleeding hypersensitivity to any component of this product benign or malignant liver tumors acute liver disease

Adverse Reactions:

Adverse reactions to report suspected adverse reactions, contact northstar rx llc. toll-free at 1-800-206-7821 or fda at 1-800-fda-1088 or www.fda.gov/medwatch . adverse reactions reported with the use of pops include: menstrual irregularity is the most frequently reported side effect. frequent and irregular bleeding are common, while long duration of bleeding episodes and amenorrhea are less likely. headache, breast tenderness, nausea, and dizziness are increased among progestin-only oral contraceptive users in some studies. androgenic side effects such as acne, hirsutism, and weight gain occur rarely. the following adverse reactions were also reported in clinical trials or during post-marketing experience: gastrointestinal disorders: vomiting, abdominal pain; general disorders and administration site conditions: fatigue, edema; psychiatric disorders: depression, nervousness; musculoskeletal and connective tissue disorders: pain in extremity; reproductive system and breast disorders:
genital discharge; breast pain, menstruation delayed, suppressed lactation, vaginal hemorrhage, menorrhagia, withdrawal bleed when product is stopped; immune system disorders: anaphylactic/anaphylactoid reaction, hypersensitivity; hepatobiliary disorders: hepatitis, jaundice cholestatic; skin and subcutaneous tissue disorders: alopecia, rash, rash pruritic.

Overdosage:

Overdosage there have been no reports of serious ill effects from overdosage, including ingestion by children.

Description:

Description sharobel ™ tablets. each tablet contains 0.35 mg norethindrone. inactive ingredients include fd&c blue no. 1 aluminum lake, fd&c yellow no. 6 aluminum lake, titanium dioxide, polyvinyl alcohol, talc, macrogol/polyethylene glycol 3350 nf, lecithin (soya), hydromellose, lactose monohydrate, magnesium stearate, and pregelatinized starch. meets usp dissolution test 3. norethindrone structure

Clinical Pharmacology:

Clinical pharmacology 1. mode of action sharobel ™ progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle lh and fsh peaks, slowing the movement of the ovum through the fallopian tubes, and altering the endometrium. 2. pharmacokinetics serum progestin levels peak about two hours after oral administration, followed by rapid distribution and elimination. by 24 hours after drug ingestion, serum levels are near baseline, making efficacy dependent upon rigid adherence to the dosing schedule. there are large variations in serum levels among individual users. progestin-only administration results in lower steady-state serum progestin levels and a shorter elimination half-life than concomitant administration with estrogens.

How Supplied:

How supplied sharobel™ (0.35 mg norethindrone tablets, usp) is available in a compact card (ndc 16714-441-01) containing 28 green, biconvex, round tablets imprinted "v2" on one side. sharobel™ is available in the following configurations: carton of 1 ndc 16714-441-02 carton of 3 ndc 16714-441-03 carton of 6 ndc 16714-441-04 store at 20° to 25°c (68° to 77°f). [see usp for controlled room temperature.] keep out this and all medication of the reach of children. reference 1. mccann m, and potter l. progestin-only oral contraceptives: a comprehensive review. contraception, 50:60 (suppl. 1), december 1994. 2. van giersbergen plm, halabi a, dingemanse j. pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. int j clin pharmacol ther 2006;44(3):113-118. 3. truitt st, fraser a, gallo me, lopez lm, grimes da and schulz kf. combined hormonal versus nonhormonal versus progestin-only contraception in lactation (review).
the cochrane collaboration. 2007, issue 3. 4. halderman, ld and nelson al. impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. am j obstet gynecol.; 186 (6): 1250-1258. 5. ostrea em, mantaring iii jb, silvestre ma. drugs that affect the fetus and newborn infant via the placenta or breast milk. pediatr clin n am; 51(2004): 539-579. 6. cooke id, back dj, shroff ne: norethisterone concentration in breast milk and infant and maternal plasma during ethynodiol diactetate administration. contraception 1985; 31:611-21. 7. 2008 uspc official:12/1/08-4/30/09, usp monographs: norethindrone tablets (page 1 of 5).

Spl Patient Package Insert:

Detailed patient labeling sharobel™ (norethindrone tablets, usp) this product (like all oral contraceptives) is used to prevent pregnancy. it does not protect against hiv infection (aids) or other sexually transmitted diseases. description sharobel™ tablets each tablet contains 0.35 mg norethindrone. inactive ingredients include fd&c blue no. 1 aluminum lake, fd&c yellow no. 6 aluminum lake, titanium dioxide, polyvinyl alcohol, talc, macrogol/polyethylene glycol 3350 nf, lecithin (soya), hydromellose, lactose monohydrate, magnesium stearate, and pregelatinized starch. introduction this leaflet is about birth control pills that contain one hormone, a progestin. please read this leaflet before you begin to take your pills. it is meant to be used along with talking with your healthcare professional. progestin-only pills are often called "pops" or "the minipill." pops have less progestin than the combined birth control pill (or "the pill") which contains both an estrogen and a pr
ogestin. how effective are pops? about 1 in 200 pop users will get pregnant in the first year if they all take pops perfectly (that is, on time, every day). about 1 in 20 "typical" pop users (including women who are late taking pills or miss pills) gets pregnant in the first year of use. table 2 will help you compare the efficacy of different methods. sharobel™ tablets have not been studied for and are not indicated for use in emergency contraception. how do pops work? pops can prevent pregnancy in different ways including: they make the cervical mucus at the entrance to the womb (the uterus) too thick for the sperm to get through to the egg. they prevent ovulation (release of the egg from the ovary) in about half of the cycles. they also affect other hormones, the fallopian tubes and the lining of the uterus. you should not take pops if there is any chance you may be pregnant. if you have breast cancer. if you have bleeding between your periods that has not been diagnosed. if you are taking certain drugs for epilepsy (seizures) or for tb, or medicine for pulmonary hypertension or certain herbal products. (see "using pops with other medicines" below.) if you are hypersensitive, or allergic, to any component of this product. if you have liver tumors, either benign or cancerous. if you have acute liver disease. risks of taking pops cigarette smoking greatly increases the possibility of suffering heart attacks and strokes. women who use oral contraceptives are strongly advised not to smoke. warning: if you have sudden or severe pain in your lower abdomen or stomach area, you may have an ectopic pregnancy or an ovarian cyst. if this happens, you should contact your healthcare professional immediately. ectopic pregnancy an ectopic pregnancy is a pregnancy outside the womb. because pops protect against pregnancy, the chance of having a pregnancy outside the womb is very low. if you do get pregnant while taking pops, you have a slightly higher chance that the pregnancy will be ectopic than do users of some other birth control methods. ovarian cysts these cysts are small sacs of fluid in the ovary. they are more common among pop users than among users of most other birth control methods. they usually disappear without treatment and rarely cause problems. cancer of the reproductive organs and breasts some studies in women who use combined oral contraceptives that contain both estrogen and a progestin have reported an increase in the risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. there is insufficient data to determine whether the use of pops similarly increases this risk. a meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years. this increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. there was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use. some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. however, this finding may be related to factors other than the use of oral contraceptives and there is insufficient data to determine whether the use of pops increases the risk of developing cancer of the cervix. liver tumors in rare cases, combined oral contraceptives can cause benign but dangerous liver tumors. these benign liver tumors can rupture and cause fatal internal bleeding. in addition, some studies report an increased risk of developing liver cancer among women who use combined oral contraceptives. however, liver cancers are rare. there is insufficient data to determine whether pops increase the risk of liver tumors. diabetic women diabetic women taking pops do not generally require changes in the amount of insulin they are taking. however, your healthcare professional may monitor you more closely under these conditions. sexually transmitted diseases (stds) warning: pops do not protect against getting or giving someone hiv (aids) or any other std, such as chlamydia, gonorrhea, genital warts or herpes. side effects irregular bleeding: the most common side effect of pops is a change in menstrual bleeding. your periods may be either early or late, and you may have some spotting between periods. taking pills late or missing pills can result in some spotting or bleeding. other side effects: less common side effects include headaches, tender breasts, nausea, vomiting, dizziness, and fatigue. depression, nervousness, leg pain, vaginal discharge, fluid retention, allergic reactions, jaundice or a yellowing of the skin or eyeballs, loss of scalp hair, rash/itchy rash, weight gain, acne and extra hair on your face and body have been reported, but are rare. if you are concerned about any of these side effects, check with your healthcare professional. using pops with other medicines before taking a pop, inform your healthcare professional of any other medication, including over-the-counter medicine, that you may be taking. these medicines can make pops less effective: medicines for seizures such as: ● phenytoin (dilantin ® ) ● carbamazepine (tegretol) ● phenobarbital medicine for tb: ● rifampin (rifampicin) medicine for pulmonary hypertension such as: ● bosentan (tracleer®) herbal products such as: ● st. john’s wort before you begin taking any new medicines be sure your healthcare professional knows you are taking a progestin-only birth control pill. how to take pops important points to remember pops must be taken at the same time every day, so choose a time and then take the pill at that same time every day. every time you take a pill late, and especially if you miss a pill, you are more likely to get pregnant. start the next pack the day after the last pack is finished. there is no break between packs. always have your next pack of pills ready. you may have some menstrual spotting between periods. do not stop taking your pills if this happens. if you vomit soon after taking a pill, use a backup method (such as a condom and/or a spermicide) for 48 hours. if you want to stop taking pops, you can do so at any time, but, if you remain sexually active and don’t wish to become pregnant, be certain to use another birth control method. if you are not sure about how to take pops, ask your healthcare professional. starting pops it’s best to take your first pop on the first day of your menstrual period. if you decide to take your first pop on another day, use a backup method (such as a condom and/or a spermicide) every time you have sex during the next 48 hours. if you have had a miscarriage or an abortion, you can start pops the next day. if you are late or miss taking your pops ● if you are more than 3 hours late or you miss one or more pops: 1. take a missed pill as soon as you remember that you missed it, 2. then go back to taking pops at your regular time, 3. but be sure to use a backup method (such as a condom and/or a spermicide) every time you have sex for the next 48 hours. ● if you are not sure what to do about the pills you have missed, keep taking pops and use a backup method until you can talk to your healthcare professional. if you are breastfeeding if you are fully breastfeeding (not giving your baby any food or formula), you may start your pills 6 weeks after delivery. if you are partially breastfeeding (giving your baby some food or formula), you should start taking pills by 3 weeks after delivery. if you are switching pills if you are switching from the combined pills to pops, take the first pop the day after you finish the last active combined pill. do not take any of the 7 inactive pills from the combined pill pack. you should know that many women have irregular periods after switching to pops, but this is normal and to be expected. if you are switching from pops to the combined pills, take the first active combined pill on the first day of your period, even if your pops pack is not finished. if you switch to another brand of pops, start the new brand anytime. if you are breastfeeding, you can switch to another method of birth control at any time, except do not switch to the combined pills until you stop breastfeeding or at least until 6 months after delivery. pregnancy while on the pill if you think you are pregnant, contact your healthcare professional. even though research has shown that pops do not cause harm to the unborn baby, it is always best not to take any drugs or medicines that you don’t need when you are pregnant. you should get a pregnancy test: if your period is late and you took one or more pills late or missed taking them and had sex without a backup method. anytime it has been more than 45 days since the beginning of your last period. will pops affect your ability to get pregnant later? if you want to become pregnant, simply stop taking pops. pops will not delay your ability to get pregnant. breastfeeding if you are breastfeeding, pops will not affect the quality or amount of your breast milk or the health of your nursing baby. however, isolated cases of decreased milk production have been reported. overdose no serious problems have been reported when many pills were taken by accident, even by a small child, so there is usually no reason to treat an overdose. other questions or concerns if you have any questions or concerns, check with your healthcare professional. you can also ask for the more detailed "professional labeling" written for doctors and other healthcare professionals. how to store your pops store at 20° to 25°c (68° to 77°f). [see usp for controlled room temperature.] rx only keep out this and all medication of the reach of children. manufactured for: northstar rx llc memphis, tn 38141 manufactured by: novast laboratories ltd. nantong, china 226009 i0066 iss.11/2015 rev.a

Package Label Principal Display Panel:

Package label.principal display panel sharobel™ (norethindrone tablets usp, 0.35 mg) rx only carton table i table ii


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.